Effects of Amino Acid Feedings in Schizophrenic Patients Treated with Iproniazid

  title={Effects of Amino Acid Feedings in Schizophrenic Patients Treated with Iproniazid},
  author={William Pollin and Philippe V. Cardon and Seymour S. Kety},
  pages={104 - 105}
Large oral doses of individual amino acids were given three or four times daily for periods of 1 week to schizophrenic patients, some of whom were maintained on iproniazid. Marked alterations in behavior in some patients were associated with the administration of l-methionine and of l-tryptophan. 

Metabolic Effects of Methionine in Schizophrenic Patients pretreated with a Monoamine Oxidase Inhibitor

One of the purposes of the present experiments is to determine whether methionine increases the rates of N or O-methylation of catechol and indolic amines.

Nicotinic Acid in the Prevention and Treatment of Methionine-Induced Exacerbation of Psychopathology in Schizophrenics *

Nicotinic acid failed to prevent by prior administration or to relieve by subsequent administration, the methionine-tranylcypromine-induced exacerbation of psychopathology, and the possibility of a toxic psychosis due to the metabolite, methamphetamineionine sulfoximine, must be seriously considered.

Central-nervous-system effects of ingestin of L-tryptophan by normal subjects.

It is found that combined therapy with tryptophan and iproniazid had more therapeutic effect on psychotic patients than ipronsiazid alone, and administration of tryPTophan to subjects receiving monoamine oxidase inhibitors produced hyperreflexia, clonus and euphoria.

Endogenous Metabolic Factor in Schizophrenic Behavior

Exacerbations of schizophrenic behavior are associated with elevations of urinary tryptophan metabolites and some of the apparently spontaneous activations of psychotic symptoms may be intensified by the endogenous liberation of these two compounds.

L-tryptophan in mania. Contribution to a permissive hypothesis of affective disorders.

Five manic patients were treated with chlorpromazine hydrochloride (CPZ), then with L-tryptophan (LTP), and five with LTP first, then CPZ, in a double-blind, placebo-controlled crossover study. LTP

Aspects of tyrosine metabolism in schizophrenia

  • C. Williams
  • Medicine, Psychology
    Psychological Medicine
  • 1971
In only one parameter, excretion of free p-hydroxyphenylacetic acid, was any significant difference observed between the groups, and this is discussed in relation to some of the biochemical theories advanced from time to time for schizophrenia.

Transmethylation hypothesis of schizophrenia: methionine and nicotinic acid.

The transmethylation hypothesis of schizophrenia was reviewed with considerations that large doses of methionine when combined with a monoamine oxidase inhibitor lead to exacerbation of psychotic

The amino-hepato-entero-toxic theory of schizophrenia: an historical evaluation

On the 17th February, 1921, Vito Maria Buscaino, while boiling for a few minutes 5 ml of urine from an acute schizophrenic together with 25 ml of 5% silver nitrate, observed the immediate formation

The comparative antidepressant value of L-tryptophan and imipramine with and without attempted potentiation by liothyronine.

None of the treatments tested seemed to benefit any particular symptom of depression differenntially, and L-tryptophan had no specific effect on the sleep deficit of the syndrome.

l-Tryptophan in affective disorders: Indoleamine changes and differential clinical effects

Marked changes in cerebro-spinal fluid, platelet and urinary levels of serotonin and 5-hydroxyindoleacetic acid in patients with bipolar affective disorder suggest that the low response rate of severely depressed patients is probably not attributable to impaired l-tryptophan metabolism during depression.



Serum Glutamic Oxalacetic Transaminase Content in Hypothermia

When the body temperature of pentobarbitalized dogs was lowered, by surface-immersion technique, to 27�-26�C, elevations in serum glutamic oxalacetic transaminase were found only after a period of

National Institutes of Health Symposium on Catecholamines

  • 1958

Nervous Mental

  • Disease 125,
  • 1957